Latest news from the FASST trial
The purpose of this study is to evaluate the effectiveness and safety of IVA337 for the treatment of Diffuse Cutaneous Systemic Sclerosis.
Read latest newsletter on the research: FASST Newsletter, May2016
news & events
The northern hemisphere is entering autumn and winter and so is the seasonal influenza.
Do you have diffuse scleroderma? Your help is needed in this survey.
The Swedish member of FESCA got a second place award in Sweden.